交易 ORIC Pharmaceuticals, Inc. - ORIC CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | 0.05 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Oric Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Jun 7, 2023 | 5.67 | 0.39 | 7.39% | 5.28 | 5.89 | 5.28 |
Jun 6, 2023 | 5.47 | 0.16 | 3.01% | 5.31 | 5.61 | 5.23 |
Jun 5, 2023 | 5.28 | 0.05 | 0.96% | 5.23 | 5.31 | 5.06 |
Jun 2, 2023 | 5.26 | -0.01 | -0.19% | 5.27 | 5.40 | 5.26 |
Jun 1, 2023 | 5.25 | 0.27 | 5.42% | 4.98 | 5.36 | 4.89 |
May 31, 2023 | 4.97 | 0.07 | 1.43% | 4.90 | 5.01 | 4.86 |
May 30, 2023 | 5.01 | -0.03 | -0.60% | 5.04 | 5.08 | 4.94 |
May 26, 2023 | 5.01 | 0.00 | 0.00% | 5.01 | 5.11 | 4.99 |
May 25, 2023 | 5.13 | 0.04 | 0.79% | 5.09 | 5.16 | 4.97 |
May 24, 2023 | 5.13 | -0.01 | -0.19% | 5.14 | 5.20 | 4.99 |
May 23, 2023 | 5.16 | -0.03 | -0.58% | 5.19 | 5.41 | 5.13 |
May 22, 2023 | 5.19 | 0.26 | 5.27% | 4.93 | 5.20 | 4.93 |
May 19, 2023 | 4.94 | 0.02 | 0.41% | 4.92 | 5.04 | 4.89 |
May 18, 2023 | 4.91 | -0.02 | -0.41% | 4.93 | 5.01 | 4.85 |
May 17, 2023 | 4.96 | 0.02 | 0.40% | 4.94 | 5.05 | 4.83 |
May 16, 2023 | 4.99 | -0.10 | -1.96% | 5.09 | 5.17 | 4.95 |
May 15, 2023 | 5.10 | 0.00 | 0.00% | 5.10 | 5.21 | 5.01 |
May 12, 2023 | 5.08 | -0.12 | -2.31% | 5.20 | 5.20 | 5.05 |
May 11, 2023 | 5.15 | 0.07 | 1.38% | 5.08 | 5.25 | 4.99 |
May 10, 2023 | 5.12 | 0.26 | 5.35% | 4.86 | 5.27 | 4.85 |
ORIC Pharmaceuticals, Inc. Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Wednesday, June 14, 2023 | ||
时间(协调世界时) (UTC) 15:00 | 国家/地区 US
| 事件 Oric Pharmaceuticals Inc Annual Shareholders Meeting Oric Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Friday, June 16, 2023 | ||
时间(协调世界时) (UTC) 15:00 | 国家/地区 US
| 事件 Oric Pharmaceuticals Inc Annual Shareholders Meeting Oric Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, August 9, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 国家/地区 US
| 事件 Q2 2023 Oric Pharmaceuticals Inc Earnings Release Q2 2023 Oric Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
时间(协调世界时) (UTC) 21:05 | 国家/地区 US
| 事件 Q3 2023 Oric Pharmaceuticals Inc Earnings Release Q3 2023 Oric Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 91.767 | 78.871 | 74.186 | 28.569 | 22.371 |
销售/一般/行政费用,总计 | 25.087 | 22.013 | 13.422 | 5.725 | 3.345 |
研究与开发 | 66.68 | 56.858 | 35.921 | 22.844 | 19.026 |
营业收入 | -91.767 | -78.871 | -74.186 | -28.569 | -22.371 |
利息收入(费用),非经营净值 | 2.645 | 0.141 | 0.306 | 1.397 | 0.775 |
其他,净值 | 0 | 0.015 | 0.177 | 0.289 | 0.233 |
税前净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
税后净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
未计算非常项目前的净收益 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
普通股股东可获收益 (不含非经常性项目) | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
普通股股东可获收益 (含非經常性項目) | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
摊薄净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
摊薄后加权平均股 | 39.6553 | 37.9543 | 21.9425 | 27.5424 | 27.5424 |
扣除特别项目的每股摊薄盈利 | -2.24742 | -2.07394 | -3.35892 | -0.97606 | -0.77564 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
每股正常摊薄盈利 | -2.24742 | -2.07394 | -2.22673 | -0.97606 | -0.77564 |
异常费用(收入) | 0 | 24.843 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 25.678 | 22.119 | 25.694 | 20.696 | 23.258 |
销售/一般/行政费用,总计 | 6.162 | 5.824 | 5.971 | 6.862 | 6.43 |
研究与开发 | 19.516 | 16.295 | 19.723 | 13.834 | 16.828 |
营业收入 | -25.678 | -22.119 | -25.694 | -20.696 | -23.258 |
利息收入(费用),非经营净值 | 1.733 | 1.272 | 0.865 | 0.409 | 0.099 |
其他,净值 | 0 | ||||
税前净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
税后净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
未计算非常项目前的净收益 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
普通股股东可获收益 (不含非经常性项目) | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
普通股股东可获收益 (含非經常性項目) | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
摊薄净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
摊薄后加权平均股 | 45.0902 | 40.1305 | 39.5757 | 39.4816 | 39.4317 |
扣除特别项目的每股摊薄盈利 | -0.53105 | -0.51948 | -0.62738 | -0.51383 | -0.58732 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.53105 | -0.51948 | -0.62738 | -0.51383 | -0.58732 |
异常费用(收入) |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 210.457 | 240.522 | 296.697 | 89.999 | 43.724 |
现金和短期投资 | 206.272 | 236.979 | 293.6 | 89.159 | 42.636 |
现金等价物 | 66.84 | 226.006 | 78.446 | 89.159 | 42.636 |
Prepaid Expenses | 4.185 | 3.543 | 3.097 | 0.84 | 1.088 |
Total Assets | 247.178 | 298.642 | 298.997 | 94.093 | 46.734 |
Property/Plant/Equipment, Total - Net | 3.253 | 2.413 | 1.981 | 2.241 | 2.514 |
Property/Plant/Equipment, Total - Gross | 9.046 | 7.402 | 6.466 | 5.756 | 5.092 |
Accumulated Depreciation, Total | -5.793 | -4.989 | -4.485 | -3.515 | -2.578 |
Other Long Term Assets, Total | 11.517 | 12.321 | 0.319 | 1.853 | 0.496 |
Total Current Liabilities | 15.388 | 15.151 | 9.002 | 5.354 | 2.596 |
Accounts Payable | 1.32 | 1.886 | 0.757 | 0.152 | 0.446 |
Accrued Expenses | 14.068 | 13.265 | 7.699 | 4.668 | 1.597 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.546 | 0.534 | 0.553 | |
Total Liabilities | 24.827 | 25.666 | 9.221 | 6.119 | 3.894 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 9.439 | 10.515 | 0.219 | 0.765 | 1.298 |
Total Equity | 222.351 | 272.976 | 289.776 | 87.974 | 42.84 |
Preferred Stock - Non Redeemable, Net | 178.058 | 107.266 | |||
Common Stock | 0.005 | 0.004 | 0.004 | 0.001 | 0.001 |
Additional Paid-In Capital | 557.867 | 518.183 | 456.196 | 2.605 | 1.38 |
Retained Earnings (Accumulated Deficit) | -335.521 | -245.211 | -166.424 | -92.69 | -65.807 |
Total Liabilities & Shareholders’ Equity | 247.178 | 298.642 | 298.997 | 94.093 | 46.734 |
Total Common Shares Outstanding | 45.0895 | 39.4301 | 36.6724 | 27.5424 | 27.5424 |
短期投资 | 139.432 | 10.973 | 215.154 | ||
Long Term Investments | 21.951 | 43.386 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 193.164 | 210.457 | 198.685 | 233.526 | 239.085 |
现金和短期投资 | 189.629 | 206.272 | 193.659 | 227.064 | 234.622 |
现金等价物 | 58.99 | 66.84 | 29.076 | 49.08 | 112.644 |
短期投资 | 130.639 | 139.432 | 164.583 | 177.984 | 121.978 |
Prepaid Expenses | 3.535 | 4.185 | 5.026 | 6.462 | 4.463 |
Total Assets | 226.648 | 247.178 | 237.997 | 259.684 | 275.062 |
Property/Plant/Equipment, Total - Net | 3.112 | 3.253 | 3.049 | 3.005 | 2.463 |
Property/Plant/Equipment, Total - Gross | 9.158 | 9.046 | 8.684 | 8.456 | 7.692 |
Accumulated Depreciation, Total | -6.046 | -5.793 | -5.635 | -5.451 | -5.229 |
Other Long Term Assets, Total | 11.063 | 11.517 | 11.953 | 12.381 | 11.937 |
Total Current Liabilities | 14.867 | 15.388 | 13.284 | 12.474 | 11.817 |
Accounts Payable | 1.93 | 1.32 | 1.532 | 2.093 | 0.888 |
Accrued Expenses | 12.937 | 14.068 | 11.752 | 10.381 | 10.929 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23.836 | 24.827 | 23.178 | 22.814 | 21.983 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 8.969 | 9.439 | 9.894 | 10.34 | 10.166 |
Total Equity | 202.812 | 222.351 | 214.819 | 236.87 | 253.079 |
Common Stock | 0.005 | 0.005 | 0.004 | 0.004 | 0.004 |
Additional Paid-In Capital | 561.481 | 557.867 | 529.945 | 526.651 | 522.144 |
Retained Earnings (Accumulated Deficit) | -358.674 | -335.521 | -315.13 | -289.785 | -269.069 |
Total Liabilities & Shareholders’ Equity | 226.648 | 247.178 | 237.997 | 259.684 | 275.062 |
Total Common Shares Outstanding | 45.0912 | 45.0895 | 39.576 | 39.5755 | 39.4386 |
Long Term Investments | 19.309 | 21.951 | 24.31 | 10.772 | 21.577 |
Other Current Liabilities, Total | |||||
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
经营活动产生的现金 | -75.143 | -59.541 | -45.268 | -23.533 | -20.683 |
经营活动产生的现金 | 0.966 | 0.897 | 0.97 | 1.028 | 0.903 |
非现金物品 | 13.458 | 14.204 | 25.42 | 1.102 | 0.484 |
营运资金的变化 | -0.445 | 4.073 | 2.045 | 1.22 | -0.707 |
投资活动产生的现金 | -109.248 | 158.435 | -215.959 | -0.768 | -0.508 |
资本支出 | -2.078 | -0.939 | -0.667 | -0.768 | -0.525 |
其他投资现金流量项目,总计 | -107.17 | 159.374 | -215.292 | 0 | 0.017 |
融资活动产生的现金 | 25.225 | 49.134 | 250.514 | 70.824 | 38.008 |
融资现金流项目 | -0.399 | -1.852 | -21.237 | -0.099 | 0 |
股票的发行(报废),净额 | 25.624 | 50.986 | 271.751 | 70.923 | 38.008 |
现金净变化 | -159.166 | 148.028 | -10.713 | 46.523 | 16.817 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -23.945 | -89.122 | -68.275 | -43.446 | -23.159 |
Cash From Operating Activities | -20.628 | -75.143 | -59.814 | -40.494 | -22.718 |
Cash From Operating Activities | 0.253 | 0.966 | 0.719 | 0.498 | 0.251 |
Non-Cash Items | 2.753 | 13.458 | 10.908 | 7.985 | 3.987 |
Changes in Working Capital | 0.311 | -0.445 | -3.166 | -5.531 | -3.797 |
Cash From Investing Activities | 12.778 | -109.248 | -137.548 | -136.863 | -90.66 |
Capital Expenditures | -0.31 | -2.078 | -1.791 | -1.39 | -0.723 |
Other Investing Cash Flow Items, Total | 13.088 | -107.17 | -135.757 | -135.473 | -89.937 |
Cash From Financing Activities | 0 | 25.225 | 0.432 | 0.431 | 0.016 |
Issuance (Retirement) of Stock, Net | 0 | 25.624 | 0.432 | 0.431 | 0.016 |
Net Change in Cash | -7.85 | -159.166 | -196.93 | -176.926 | -113.362 |
Financing Cash Flow Items | -0.399 | 0 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Pfizer Inc | Corporation | 11.9227 | 5376344 | 5376344 | 2022-12-23 | MED |
Fidelity Management & Research Company LLC | Investment Advisor | 8.8843 | 4006224 | -9509 | 2023-03-31 | LOW |
The Column Group LP | Venture Capital | 7.9129 | 3568181 | 0 | 2023-03-31 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 7.58 | 3418068 | 0 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 5.0288 | 2267642 | -166208 | 2023-03-31 | HIGH |
Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 4.4668 | 2014241 | 0 | 2023-03-31 | LOW |
Suvretta Capital Management, LLC | Hedge Fund | 4.2194 | 1902643 | 0 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.6437 | 1643074 | 96789 | 2023-03-31 | LOW |
Prosight Capital | Hedge Fund | 3.4262 | 1545000 | 365000 | 2023-03-31 | HIGH |
SilverArc Capital Management, LLC | Hedge Fund | 3.1844 | 1435945 | 199649 | 2023-03-31 | HIGH |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 3.0481 | 1374468 | -233100 | 2023-03-31 | LOW |
Boxer Capital, L.L.C. | Hedge Fund | 2.3374 | 1054000 | 0 | 2023-03-31 | LOW |
Invus Financial Advisors, LLC | Hedge Fund | 2.2344 | 1007575 | 0 | 2023-03-31 | LOW |
Chacko (Jacob M) | Individual Investor | 1.811 | 816652 | 3471 | 2023-03-31 | LOW |
Euclidean Capital, L.L.C. | Investment Advisor | 1.6578 | 747550 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5144 | 682888 | -107508 | 2023-03-31 | LOW |
Memorial Sloan-Kettering Cancer Center | Investment Advisor | 1.3356 | 602272 | 0 | 2023-03-31 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 1.2825 | 578303 | -24484 | 2023-03-31 | LOW |
Monaco asset management S.A.M. | Investment Advisor | 1.2236 | 551749 | -5681 | 2023-03-31 | HIGH |
Oppenheimer Asset Management Inc. | Investment Advisor | 0.8538 | 385011 | 0 | 2023-03-31 | LOW |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
ORIC Pharmaceuticals, Inc. Company profile
关于 ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc.是一家临床阶段的生物制药公司,致力于通过克服癌症的抗药性来改善患者的生活。 公司专注于开发多样化的疗法,旨在利用其在三个特定领域的经验来对抗癌症的抗药性机制:激素依赖性癌症、精准肿瘤学和关键肿瘤依赖性。 其候选产品包括ORIC-101、ORIC-533、ORIC-944和ORIC-114。 公司的ORIC-101是一种强效和选择性的糖皮质激素受体(GR)的小分子拮抗剂,该受体与各种实体瘤对多类癌症治疗药物的抗性有关。 公司的第二个候选产品ORIC-533是一种可口服的CD73小分子抑制剂,CD73是化疗和免疫疗法治疗方案中腺苷途径的一个关键节点。 其ORIC-944正在开发用于治疗前列腺癌和乳腺癌。
Industry: | Bio Therapeutic Drugs |
240 E. Grand Ave.
2Nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。